Tandem Diabetes Care, Inc.
TNDM
Positions held
Your positionsTNDM isn't in your positions.
Add it to see shares, cost, and P&L here.
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-08.
- Tandem Diabetes Care is positioned in the growing diabetes management market, with increasing demand for innovative medical devices.
- Revenue increased by 3% compared to the prior quarter, reaching $255 million.
- Gross margin improved to 56.9%, up from 55.3% in the previous quarter.
- The company has a high debt-to-equity ratio of 566.96, indicating significant financial leverage and risk.
- Net income for 2025 is projected to be -$204.71 million, reflecting ongoing profitability challenges.
- The overall score indicates a 'Sell' signal with a score of -12.00, suggesting negative market sentiment.
Fundamentals
| Market cap | $1.09B | Enterprise value | $1.37B | Trailing P/E | — | Forward P/E | 98.61 |
| PEG | — | Price / book | 8.36 | Beta | 1.66 | Dividend yield | 0.00% |
| Revenue growth | 5.8% | Earnings growth | — | Gross margin | 56.0% | Operating margin | -5.4% |
| Profit margin | -6.1% | ROE | -48.0% | ROA | -2.6% | Debt / equity | 5.67 |
| Current ratio | 3.18 | Free cash flow | -$43.95M | Analyst recommendation | buy | Mean target | $27.86 |
| 52w high | $29.65 | 52w low | $12.26 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $255M | $247M | $290M | $249M | $241M | — |
| Op margin | -5.4% | -7.1% | 2.9% | -9.2% | -13.2% | — |
| Net income | -$21.2M | -$20.4M | -$0.6M | -$21.2M | -$52.4M | — |
| Gross margin | 56.9% | 55.3% | 57.7% | 53.9% | 52.3% | — |
| Gross profit | $145M | $137M | $167M | $134M | $126M | — |
| Operating income | -$13.8M | -$17.4M | $8.3M | -$22.9M | -$31.9M | — |
- Revenue +3% vs prior quarter ($255M vs $247M).
- Gross margin 56.9% (was 55.3% prior quarter).
- Operating margin expanded to -5.4%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $1.0B | $940M | $748M | $801M | — |
| Op margin | -16.5% | -10.5% | -31.2% | -11.6% | — |
| Net income | -$205M | -$96.0M | -$223M | -$94.6M | — |
| Gross margin | 53.8% | 52.1% | 49.2% | 51.5% | — |
| Gross profit | $546M | $490M | $368M | $413M | — |
| Operating income | -$167M | -$99.1M | -$233M | -$92.8M | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-07 · Flutter upgraded, AppFolio downgraded: Wall Street's top analyst calls
2026-10-01 · Tandem Diabetes Care to Announce Third Quarter 2026 Financial Results on November 5, 2026
2026-10-01 · Tandem Diabetes Care (TNDM) Is Up 7.2% After International Launch Of Mobi Insulin Pump System
2026-09-30 · Q2 Earnings Highlights: Tandem Diabetes (NASDAQ:TNDM) Vs The Rest Of The Healthcare Technology Stocks
2026-09-28 · Sector Update: Healthcare Stocks Lean Lower Premarket Monday
2026-09-28 · Tandem Diabetes Expands Insulin Delivery System to 12 New Countries
2026-09-28 · Tandem Mobi Automated Insulin Delivery System Now Available in Twelve International Markets
2026-09-24 · Truist Lowers Price Target on Tandem Diabetes Care to $28 From $31, Keeps Buy Rating
2026-09-20 · Is Tandem Diabetes Care (TNDM) Undervalued As Investors Weigh Its 34% One Year Return?
2026-09-18 · 3 Cash-Burning Stocks with Questionable Fundamentals
2026-09-17 · Tandem Diabetes Care (TNDM) Soars 7.7%: Is Further Upside Left in the Stock?
Price (daily)
Full chart · RSI · MACD · patterns